---
title: "Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301809077.md"
description: "Global cancer drug spending is projected to exceed $400 billion by 2028, up from $252 billion in 2024, with the US accounting for 46%. Recent FDA approvals include daraxonrasib for pancreatic cancer and therapies for breast and colon cancers. Key companies like Oncolytics Biotech and Revolution Medicines are advancing treatments targeting RAS-mutant colorectal and pancreatic cancers, with significant clinical trial data expected soon."
datetime: "2026-10-14T08:07:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301809077.md)
  - [en](https://longbridge.com/en/news/301809077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301809077.md)
generator: "portal-rs"
---

# Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

This news item displays a headline only and has no other text.

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)

## Related News & Research

- [Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients](https://longbridge.com/en/news/302871272.md)
- [Oncolytics Showcases Pelareorep Phase 2 mCRC Study Plans](https://longbridge.com/en/news/302435335.md)
- [CHMP backs RASONQUE for metastatic pancreatic cancer](https://longbridge.com/en/news/302430051.md)
- [Revolution Medicines Begins Treating Patients in Phase 3 Trial of Zoldonrasib Combination for Lung Cancer](https://longbridge.com/en/news/302419185.md)
- [ANALYSIS-Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug](https://longbridge.com/en/news/302008420.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**